Delta 9 tetrahydrocannabinol - PhytoPain Pharma

Drug Profile

Delta 9 tetrahydrocannabinol - PhytoPain Pharma

Alternative Names: Cannabidiol; Delta-9-tetrahydrocannibinol; PPP-001; Smokeable marijuana

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhytoPain Pharma
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Complex regional pain syndromes
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer pain

Most Recent Events

  • 19 Mar 2018 PhytoPain Pharma has been acquired by Tetra Bio Pharma
  • 14 Mar 2018 Delta 9 tetrahydrocannabinol - PhytoPain Pharma receives Orphan Drug status for Complex regional pain syndromes in USA
  • 06 Feb 2018 Tetra BioPharma intends to file for a Drug Identification Number (DIN) for PPP 001 to Health Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top